# Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer

> **NCT01157091** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 28 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Recurrent Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** pazopanib hydrochloride
- **OTHER:** laboratory biomarker analysis
- **OTHER:** immunologic technique

## Key facts

- **NCT ID:** NCT01157091
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-08
- **Primary completion:** 2013-10-17
- **Final completion:** 2013-12-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01157091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01157091, "Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01157091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*